TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Prostatype Genomics AB
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Turnover |
129
|
911
|
456 |
| Financial expenses |
1,089
|
1,472
|
265 |
| Earnings before taxes |
-26,661
|
-27,831
|
-19,437 |
| EBITDA |
-25,247
|
-25,102
|
-17,899 |
| Total assets |
27,258
|
33,061
|
20,682 |
| Current assets |
7,680
|
17,403
|
9,468 |
| Current liabilities |
5,521
|
16,444
|
2,895 |
| Equity capital |
21,737
|
16,572
|
17,475 |
| - share capital |
435
|
4,815
|
917 |
| Employees (average) |
6
|
7
|
6 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Solvency |
79.7%
|
50.1%
|
84.5% |
| Turnover per employee |
22
|
130
|
76 |
| Profit as a percentage of turnover |
-20667.4%
|
-3055.0%
|
-4262.5% |
| Return on assets (ROA) |
-93.8%
|
-79.7%
|
-92.7% |
| Current ratio |
139.1%
|
105.8%
|
327.0% |
| Return on equity (ROE) |
-122.7%
|
-167.9%
|
-111.2% |
| Change turnover |
-751
|
452
|
450 |
| Change turnover % | -85% | 6730% | |
| Chg. No. of employees |
-1
|
1
|
1 |
| Chg. No. of employees % | -14% | 20% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.